ChemicalBook Product Catalog Pharmaceutical intermediates Heterocyclic compound DR2313 | PARP inhibitor

DR2313 | PARP inhibitor

Product NameDR2313 | PARP inhibitor
CAS284028-90-6
MFC8H10N2OS
MW182.24
EINECS200-589-5
MOL File284028-90-6.mol

Chemical Properties

Boiling point	349.3±52.0 °C(Predicted)
Density	1.46±0.1 g/cm3(Predicted)
storage temp.	Sealed in dry,2-8°C
solubility	H2O: >2mg/mL (warmed)
pka	1.54±0.20(Predicted)
form	powder
color	white to beige
Water Solubility	H2O: >2mg/mL (warmed)
InChI	1S/C8H10N2OS/c1-5-9-7-2-3-12-4-6(7)8(11)10-5/h2-4H2,1H3,(H,9,10,11)
InChIKey	HRYKZAKEAVZGJD-UHFFFAOYSA-N
SMILES	CC1=NC(=O)C2=C(CCSC2)N1

Safety Information

WGK Germany	3
Storage Class	11 - Combustible Solids

Usage And Synthesis

Uses

DR2313 is a potent, selective, competitive and brain-penetrant inhibitor of poly(ADP-ribose) polymerase (PARP), with IC50s of 0.20 μM and 0.24 μM for PARP-1 and PARP-2, respectively. DR2313 exhibits neuroprotective effects on ischemic injuries in vitro and in vivo[1][2].

Biological Activity

Potent, competitive inhibitor of poly(ADP-ribose) polymerase (PARP) (IC 50 values are 0.20 and 0.24 μ M for PARP-1 and PARP-2 respectively). Neuroprotective; reduces neuronal cell death in models of cerebral ischemia in vivo and in vitro . Brain penetrant.

in vivo

DR2313 (3-10 mg/kg i.v. bolus or infusion for 6 h) significantly reduces the cortical infarct volume in both permanent and transient focal ischemia models in rats^[1].

Animal Model:	Male Wistar rats (220-300 g) with permanent MCA occlusions (pMCAos) and transient MCA occlusions (tMCAos)^[1]
Dosage:	3, 10 mg/kg
Administration:	I.v. bolus and i.v. infusion for 6 h beginning 5 min before the onset of ischemia
Result:	Reduced the infarct volume in a dose-dependent manner in pMCAo and tMCAo model.

IC 50

PARP-1: 0.20 μM (IC₅₀); PARP-2: 0.24 μM (IC₅₀)

References

[1] Nakajima H, et, al. A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats. J Pharmacol Exp Ther. 2005 Feb;312(2):472-81. DOI:10.1124/jpet.104.075465
[2] Xu Z, et, al. Endonuclease G does not play an obligatory role in poly(ADP-ribose) polymerase-dependent cell death after transient focal cerebral ischemia. Am J Physiol Regul Integr Comp Physiol. 2010 Jul;299(1):R215-21. DOI:10.1152/ajpregu.00747.2009

DR2313 | PARP inhibitor Supplier

DR2313 | PARP inhibitor manufacturers

Related Product Information

Send Inquriy